Jinyao Pharmaceutical Co Ltd
Jinyao Pharmaceutical Co Ltd is a Chinese pharmaceutical company that develops, produces, and sells a range of pharmaceutical products, primarily in the domestic market.
Business. Jinyao Pharmaceutical Co Ltd (600488.SS) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in China and is primarily listed on the Shanghai Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data. Consequently, the company is described at the industry level within the broader pharmaceuticals sector.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Jinyao Pharmaceutical Co Ltd (600488.SS) is a pharmaceutical company engaged in the development and sale of healthcare products. The firm is headquartered in China and is primarily listed on the Shanghai Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data. Consequently, the company is described at the industry level within the broader pharmaceuticals sector.
Jinyao Pharmaceutical maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.22, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 1.49, suggesting it has sufficient short-term assets to cover its short-term liabilities, but with limited excess. Free cash flow stands at 303,945,540 CNY, which is a positive sign for operational flexibility and reinvestment potential.
Profitability metrics show a return on equity (ROE) of 4.36% and a return on assets (ROA) of 2.34%, both of which are below the typical thresholds for high-performing pharmaceutical firms. These figures suggest that the company is generating modest returns relative to its equity and asset base. Gross profit of 1,423,564,510 CNY represents 44.27% of total revenue, which is in line with industry norms, but the operating margin of 7.02% is relatively low, indicating potential inefficiencies in cost management or pricing power.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification beyond the domestic Chinese market. This lack of diversification increases exposure to local economic and regulatory risks, which could impact revenue stability.
Looking ahead, the company's revenue is expected to grow, with the current fiscal year showing a revenue of 3,215,285,230 CNY and a trailing twelve-month revenue of 2,427,864,590 CNY. However, the growth trajectory is not yet quantified in the next fiscal year, and the capital expenditure of -77,740,240 CNY suggests a reduction in investment in new projects or facilities.
Risk factors include a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could limit its ability to fund operations or pursue growth opportunities without external financing. No significant dilution sources are identified in the current period, and the dilution risk is assessed as low.
Recent events include the latest financial filing, which provides the most recent revenue and profitability figures. No recent earnings call transcripts or major regulatory filings have been disclosed in the available data.
- Jinyao Pharmaceutical maintains a conservative capital structure with a low debt-to-equity ratio of 0.22.
- The company's ROE of 4.36% and ROA of 2.34% indicate modest returns relative to industry benchmarks.
- Revenue is concentrated in a single business segment and geographic market, increasing exposure to local risks.
- Free cash flow of 303,945,540 CNY provides some flexibility for reinvestment or dividends.
- The company faces medium liquidity risk and a low dilution risk, with no significant dilution sources identified.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Jinyao Pharmaceutical Co Ltd Market data — financials · 2026-05-27
- Jinyao Pharmaceutical Co Ltd Market data — analyst estimates · 2026-05-27